We describe phaeochromocytoma penetrance in multiple endocrine neoplasia type 2 (MEN2) according to RET protooncogene-specific mutations, and report changes in phaeochromocytoma diagnosis and management from 1968 to 2015.
This retrospective chart review included 309 MEN2 patients from one specialised ambulatory care centre. Phaeochromocytoma patients were categorised by diagnosis date: early, 1968–1996, n = 40; and recent, 1997–2015, n = 45.
Phaeochromocytoma was diagnosed in 85/309 patients with RET mutations in the following exons (phaeos/all carriers, %): exon 11 (56/120, 46·6%); exon 16 (7/17, 41·2%), exon 10 (14/47, 29·8%), and exon 13–15 (2/116, 1·7%). Age at phaeochromocytoma diagnosis differed according to affected exon: 21·9 ± 1·5 years, exon 16; 34·1 ± 11·6 years, exon 11; and 41·8 ± 8·8 years, exon 10. Age-related phaeochromocytoma penetrance differed among five amino-acid substitutions at codon 634, and was highest for Cys634Arg and Cys634Tyr. Age at diagnosis was 34·4 ± 11·6 years in the early and recent groups. Phaeochromocytoma and medullary thyroid carcinoma (MTC) were diagnosed synchronously in 21/40 (early) vs 8/45 (recent) and metachronously in 19/40 vs 37/45 cases. Diagnostic methods significantly changed from clinical (22/40 vs 4/45) to biochemical and/or imaging-based (14/40 vs 35/45). Phaeochromocytoma diameter at diagnosis was 4·6 vs 2·6 cm.
Phaeochromocytoma penetrance and age of diagnosis are highly correlated with MTC aggressiveness based on RET mutation status, with higher penetrance and younger age of diagnosis associated with more aggressive MTC. Penetrance steadily increases with age. At-risk patients require lifelong follow-up.
This article is protected by copyright. All rights reserved.